BioInvent International
23.11.2021 17:38:03 CET | ACCESS Newswire | Press release
LUND, SE / ACCESSWIRE / November 23, 2021 / BioInvent International (STO:BINV)
Friday, December 17 at 1 pm ET (7 pm CET)
BI-1206 is a Potential Treatment for non-Hodgkin's Lymphoma and Solid Tumors
BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a key opinion leader (KOL) webinar on BI-1206, a potential treatment for non-Hodgkin's lymphoma and solid tumors, on Friday, December 17, 2021 at 1:00pmET/7:00pmCET.
The webcast will feature KOL Michael Wang, M.D., from the MD Anderson Cancer Center, who will discuss the current treatment landscape and unmet medical need in treating patients with non-Hodgkin's lymphoma (NHL) and Mantle Cell Lymphoma (MCL).
BioInvent's management team will provide an update on the ongoing BI-1206 clinical studies for the treatment of non-Hodgkin's lymphoma and solid tumors, including an overview of the NHL data presented at ASH on December 11.
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
BI-1206 is a monoclonal antibody that selectivity binds to FcγRIIB (CD32B). By blocking FcγRIIB, BI-1206 can recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of NHL. In addition, BI-1206 has the potential to reduce resistance to PD-1 immune checkpoint blockade, providing a new way to enhance anti-tumor immune responses in patients with solid tumors.
To register for the event, please click here.
Luhua (Michael) Wang, M.D. is a Professor in the department of Lymphoma & Myeloma at MD Anderson. Dr. Wang obtained his M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. He completed his clinical training as a resident at Norwalk Hospital, Norwalk, Connecticut, and as a Fellow in Oncology and in Hematology at MD Anderson.
Dr. Wang has published more than 150 peer-reviewed papers and presented his work at meetings nationally and internationally. He is the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.
During the past 15 years, he has focused on preclinical and clinical research and established an MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. Dr. Wang has pioneered the work to improve the treatment of patients with MCL, including the introduction of BTK inhibitors such as ibrutinib and acalabrutinib in the treatment algorithm, and has performed extensive work with CAR-T cells for the treatment of these patients. His work has been published in the most prestigious medical journals such as the NEJM and the Lancet. He is currently the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.
About BioInvent
BioInvent International AB (Nasdaq Stockholm:BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
Attachments
BioInvent Hosting Key Opinion Leader Webinar on BI-1206
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/674388/BioInvent-Hosting-Key-Opinion-Leader-Webinar-on-BI-1206
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Appoints Stephen Sarnocinski to President - End User Research, Sales and Service - OPE Commercial Landscaping Market Global21.10.2026 16:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 21, 2026 / Stephen (Sarno) Sarnocinski is named President - End User Research, Sales and Service - OPE Commercial Landscaping Market Global, effective October 20, 2026, reporting to Joe Galli, CEO. Sarnocinski brings 21+ years of extraordinary experience, performance and leadership to Chervon. He is a high-potential senior executive with an exciting future ahead at Chervon. Sarno will now assume a new role at Chervon focused on pioneering and developing the OPE Commercial Landscaper User Vertical. Sarno was most recently a Senior Vice President - Job Site Solutions for TTI/Milwaukee, leading the Utility, Energy, Communications and Mining Verticals. Over the past 10 years he has held increasingly responsible JSS positions in the Eastern USA. Before his JSS role, he was responsible for Milwaukee East Coast Service Operations. He started his TTI/Milwaukee career rising through a series of store coverage and territory management positions. Before
DataTracks Launches Nova, Filing Software that Takes UK Micro-Entities Through HMRC and Companies House on One Set of Figures21.10.2026 15:45:00 CEST | Press release
LONDON, UK / ACCESS Newswire / October 21, 2026 / DataTracks, the regulatory reporting software and services provider, has launched DataTracks Nova, software that prepares a UK micro-entity's accounts and Corporation Tax return from a single set of figures, produces the iXBRL that HMRC requires now and Companies House will require from 1 April 2028, and files the CT600 with HMRC. Companies House accounts filing runs from the same data in the same product. Until 31 March 2026, many smaller UK companies with straightforward affairs had a free way to do this themselves. CATO (Company Accounts and Tax Online) was a free HMRC online service, run jointly with Companies House, that let a company prepare and submit its own Corporation Tax return and accounts through a simple web form, with no software to buy and no accountant needed. It was only open to companies filing without an agent. HMRC closed it on 31 March 2026. Since 1 April 2026, companies have generally had to use commercial softwar
Fermi Provides Letter to Shareholders from CEO Lee McIntire on Financing Fermi's Next Chapter21.10.2026 14:30:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / October 21, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company") today provided the following letter to shareholders from CEO Lee McIntire: Dear Fellow Shareholders, We are living through an extraordinary moment in the development of American infrastructure. As artificial intelligence reshapes industries and economies, reliable power has become one of the most strategically important and sought-after assets in the world. Fermi was founded with this opportunity in mind. At Fermi's Project Matador, we are pursuing one of the most ambitious power and infrastructure developments in the country, designed to deliver the scale and reliability required by the next generation of computing. Throughout my decades in global infrastructure and construction, I have learned that creating a successful infrastructure business requires more than assembling valuable assets. It requires judgment and financial discipline to turn th
PFN and Tenstorrent Selected for NEDO Project on "xPU Design and Development Incorporating Photonics Electronics Integration Technology"21.10.2026 14:00:00 CEST | Press release
TOKYO, JP / ACCESS Newswire / October 21, 2026 / Preferred Networks, Inc. (PFN) and Tenstorrent USA, Inc. (Tenstorrent) have announced today that their joint proposal has been selected by Japan's New Energy and Industrial Technology Development Organization (NEDO) for the theme "xPU Design and Development Incorporating Photonics-Electronics Integration Technology" (*1) under the NEDO-sponsored "Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems / Development of manufacturing technologies for advanced semiconductors." AI models and workloads continue to increase in size and computational complexity, and are being adopted across a wide range of industries. This rapid growth has further increased the compute needed for model training and inference, driving demand for more scalable and efficient AI infrastructure. Through a joint research and development project, PFN and Tenstorrent aim to develop a system-level integration of
Polaris Renewable Energy Awards Key Supply Contract and Issues Notice to Proceed on Punta Lima Battery Storage Investment20.10.2026 23:10:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / October 20, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce that it has awarded and executed a contract with Trina Energy Storage Solutions (Singapore) Pte. Ltd. ("Trina Storage") for the supply of battery energy storage systems ("BESS") for the Company's Punta Lima project in Puerto Rico. Trina Storage is a global utility-scale energy storage provider with 30 GWh of BESS projects commissioned and under execution worldwide, including more than 6 GWh across Latin America and the Caribbean. The Punta Lima BESS project is being advanced under Puerto Rico's Accelerated Storage Addition Program ("ASAP"), a strategic initiative designed to strengthen grid reliability through the deployment of utility-scale battery energy storage systems co-located with existing generation facilities. As background, on June 5, 2026, Polaris Power US, Inc. ("PPUS") fully executed the BESS Standard Offer Agreement (the "SO1 Agree
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom